X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VLS-01 (dimethyltryptamine) is a partial agonist of the 5-HT 1A/2A/2C receptors. It is currently being evaluated in the Phase I clinical trial studies for the treatment of resistant depression.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: VLS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog which is under phase 1/2 clinical development for the treatment of generalized anxiety disorder (GAD) with depressive symptoms.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Through the acquisition, combined portfolio will advance well-protected deuterated DMT program, including SPL026 (N,N-dimethyltryptamine) for the potential treatment of Major Depressive Disorder (MDD).
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cybin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 23, 2023
Details:
VLS-01 is a proprietary OTF formulation of N,N-dimethyltryptamine. Pharmacologically, DMT is a partial agonist of the 5-HT 1A/2A/2C receptors, characterized by an intrinsically short duration of psychedelic effect, with a serum half-life estimated at less than 10 minutes.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: VLS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Together, the combined operating teams of Cybin and Small Pharma create a sector-leading organization with deep expertise in N,N-dimethyltryptamine (DMT, SPL026) and deuterated psychedelic tryptamine-based therapeutics for mental health disorders.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cybin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 28, 2023
Details:
AP-188 (N,N-dimethyltryptamine) is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Sairiyo will use the net proceeds to advance developments of cepharanthine, for cancer and infectious diseases, and DMT PharmaPatch (N,N-dimethyltryptamine) as a potential treatment for ocular disease and neuropsychiatric conditions.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: PharmaPatch
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaTher
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 18, 2023
Details:
AP-188 (N,N-dimethyltryptamine), is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
CYB004 (deuterated dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
AP-188 (N,N-Dimethyltryptamine), is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
The capital raised will be used for research, development, and program management costs related to the completion of the Phase 1 DMT (N, N-dimethyltryptamine) study currently underway as well as Phase 2a stroke and traumatic brain injury (TBI) studies.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: DMT
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dalmore Group
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 03, 2023
Details:
SPL026, is a proprietary synthetic formulation of DMT (N,N-dimethyltryptamine). It is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
AP-188 (N,N-dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
AP-188 (N,N-dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
SPL026, is a proprietary synthetic formulation of DMT (N,N-dimethyltryptamine). It is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
SPL026, is a proprietary synthetic formulation of DMT (N,N-dimethyltryptamine). It is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
AP-188 (N,N-Dimethyltryptamine), is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT. The Company is advancing a clinical program of intravenous SPL026 with supportive therapy for the treatment of major depressive disorder.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
The trial will assess a single dose of SPL026 (N,N-dimethyltryptamine) in patients currently on a treatment course of SSRIs that have been ineffective in fully relieving their depression, compared to patients who are not currently using any treatment to treat their depression.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
AP-188 (N,N-dimethyltryptamine, or DMT), is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
BMND01 candidate, a novel liquid inhaled formulation of N,N-Dimethyltryptamine (“DMT”) for Treatment-Resistant Depression, possible to scale-up treatments without the need to train a whole new generation of mental health professionals.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: BMND01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
As part of the CTA, Algernon will provide cGMP DMT for the study. In return, Algernon will jointly own intellectual property around the clinical use of DMT arising from the study developed jointly by Algernon and Yale, and the option to negotiate licenses.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yale University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2022
Details:
SPL026, is a proprietary synthetic formulation of DMT being developed as a therapy for patients with major depressive disorder (MDD),to be administered by IV injection.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) under development for treatment-resistant depression (TRD) in combination with atai’s digital therapeutic designed to provide contextual “(mind)set-and-setting” support to patients prior to dosing.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: VLS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Trial is designed with fixed ascending two-dose, concentration-response study, allowing BMND01 (N,N-dimethyltryptamine) to be rapidly delivered directly into the systemic circulation in approximately 10 minutes, bypassing first-pass metabolism.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: BMND01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The Phase IIa trial study of IV SPL026 (N, N-dimethyltryptamine) in combination with psychotherapy, evaluating the efficacy of a single active dose versus placebo at two weeks, and generating a safety and tolerability dataset of SPL026 in patients with MDD.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
N,N-dimethyltryptamine and psilocybin-like prodrug, psilacetin, patch formulations are designed for patient comfort and useability. The patch design could provide a non-invasive and dose-controlled method of treatment for substance use disorders, PTSD and depression.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
The Company also confirmed in its own murine cortical neuron outgrowth preclinical study, that AP-188 (N,N-Dimethyltryptamine), in sub-psychedelic doses, increased the growth of cortical neurons by up to 40% compared to control.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The study is being conducted at two MAC Clinical Research sites and will assess the impact of SSRIs on the safety, tolerability, pharmacokinetics and pharmacodynamics of SPL026 (N,N-dimethyltryptamine) with psychotherapy in up to 24 patients.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
PSIL-001 (N,N-Dimethyltryptamine) and PSIL-002 showed similar preclinical efficacy to psilacetin, a positive control, in the forced swim test depression model without hallucinations via the head twitch response.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: PSIL-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
Ayahuasca produces powerful experiences that have been likened to intense psychotherapy, indicating its therapeutic potential for treating trauma and its resulting mental health disorders, such as post-traumatic stress disorder (PTSD).
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: Ayahuasca
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
SPL026 (N,N-dimethyltryptamine) is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
AP-188 (N,N-Dimethyltryptamine), or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
SPL026 (N,N-dimethyltryptamine) is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The Phase I/IIa clinical trial on Biomind's first innovative formulation of N,N-Dimethyltryptamine (“DMT”) is evaluating the safety, pharmacokinetics, behavioral and brain effects of BMND01, for inhaled administration.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: BMND01
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
The Mindset ‘Family 4’ compounds have shown promise in efficacy and safety at a range of doses compared to first-generation DMT and 5-MeO-DMT compounds based on rodent pre-clinical models.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug discovery program.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Terran Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 13, 2022
Details:
Tryptamine represents the core structural motif for numerous intriguing therapeutically active agents such as the classic psychedelic molecules N, N-dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: EVM202
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 in treatment of mental health conditions.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The effects of intramuscular BMND01 (N, N-dimethyltryptamine) last for about one hour, while the inhaled formulation is expected to shorten these effects to a timeframe between ten to fifteen minutes for treatment-resistant depression.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: BMND01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
BMND02 (n n-dimethyltryptamine), a serotonin 2A receptor agonist, for treatment-resistant depression under the new model of psychiatric intervention with DMT in conjunction with traditional psychological approaches.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: BMND02
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The Company’s robust tryptamine-derivative intellectual property portfolio claims novel molecules structurally related to certain naturally occurring psychedelics, such as dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience, Phase I full dataset demonstrates consistent dose-related effects on the intensity and quality of the psychedelic experience.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: SPL026
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
A novel salt form of AP-188 (N, N-dimethyltryptamine), a hallucinogenic tryptamine drug, is a new and separate structure from the original compound, helps mitigate tissue damage and promote neurogenesis demonstrated in preclinical studies.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
